Manassas, VA (PRWEB) December 03, 2013
ATCC, the premier global biological materials resource and standards organization, and Evercyte GmbH, a proven developer of immortalized human cells, have entered into a strategic partnership to develop and distribute immortalized cell lines that retain key performance characteristics of primary cells. Immortalized primary cell lines enable scientists to have a sufficient supply of physiologically relevant cells for extended studies in biological, medical, pharmaceutical, cosmetic, and toxicological research.
The partnership brings together the expertise of both organizations. Evercyte systematically establishes and functionally characterizes immortalized human cell lines from specific tissues and donors. ATCC provides extensive cell manufacturing and testing capabilities to assure the cell lines are fully defined and meet quality standards. Together, the organizations are making these unique cell lines available to the scientific community through existing global distribution channels.
“At ATCC, we’ve set the standard for providing the largest and most diverse collection of authenticated biological materials to the scientific community since 1925,” said Sharon Challberg, Principal, Corporate Development at ATCC. “Our mission is to provide biological materials for the advancement and application of scientific knowledge. This strategic partnership with Evercyte expands our ability to do so through a series of unique immortalized cell lines.”
“A key success factor of this partnership is the strength of the technical teams at both ATCC and Evercyte, given the combined years of experience in cell line development, characterization, and manufacturing,” said Chengkang Zhang, Ph.D., the technical lead for this program at ATCC.
Johannes Grillari, CSO of Evercyte, said, “Our core expertise is to systematically establish and characterize innovative, immortalized human cell cultures for cell based assays in pharmaceutical, chemical, and cosmetic industries as well as in ecotoxicology. With ATCC as a partner, high quality large-scale production of immortalized cell material is assured. Our mutual customers can develop standardized, relevant and reproducible cell based model systems and assays. In addition, ATCC’s world-wide distribution network is a perfect match for Evercyte, especially in regard to customers in academia,” Dr. Grillari added.
For more information about immortalized cell lines from ATCC and Evercyte, please visit http://www.atcc.org.
ATCC serves and supports the scientific community with industry-standard products and innovative solutions. With the world’s largest and most diverse collection of human, animal and plant cell lines, molecular genomic tools, microorganisms and biological products, ATCC is a trusted biological resource for the worldwide research community. Together, the people of ATCC share in its mission to acquire, authenticate, preserve, develop, and distribute biological materials and information for the advancement of scientific knowledge. ATCC is a non-profit organization with headquarters in Manassas, VA.
By developing immortalized cells and cell lines that retain their parental characteristics, Evercyte seeks to accelerate drug discovery and development. Evercyte produces and delivers single immortalized cell strains, including mesenchymal stem cells that can be differentiated to the cell type of interest; cell panels with cell strains derived from different tissues or from donors of various health statuses; and as a service, offers customer- tailored immortalized cell strain development as well as cell based assay development. Evercyte is a spin-off company of the Department of Biotechnology, University of Natural Resources and Life Sciences (BOKU), in Vienna, Austria.